Search

Arrowsmith (Tsukuba, Japan) completed a Series A round totaling ¥1.05 billion, with JAFCO, JIC-VGI and ANRI in the first close and DBJ Capital in the second, and held a pre-IND meeting with the US FDA on ARW001, its phage cocktail for Pseud

BiomX has dosed the first cystic fibrosis patient in its Phase 2b trial of BX004 for chronic Pseudomonas aeruginosa infections. Bacteriophage.news

PhalconBio, a Swiss biotech with an engineered-phage platform, has secured £1 million of grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy) to advance its lead anti-Pseudomonas programme. PACE named PhalconBio among the a

PhageLand was designed to combine phage-based treatment with constructed wetlands to reduce the spread of antibiotic resistance from wastewater into surface waters. Its stated project period was February 2022 to January 2025. PhageLand

In New England Biolabs’ Lessons from Lab & Life podcast, Yale’s Paul Turner expects the next 5 to 10 years to bring more clinical trials of phage therapy against targets such as lung and urinary tract infections, and says engineering phages

PUCV’s Bacteriophage and Microbial Interactions Group lists Cherry-cóctel (2024–2026), a platform for designing phage cocktails against cherry pathogens, and a Vibrio–phage coevolution project in the context of global warming (2024–2028). B

Scheduled for July 3, 2025 at the Royal Society’s Summer Science Exhibition, Franklin Nobrega’s talk “Fighting superbugs with tiny warriors” was advertised as an in-person talk with a livestream. Royal Society — exact talk programme

Invitris was selected among many strong candidates for the Orbital Bioworks Challenge by SPRIND - Bundesagentur für Sprunginnovationen. Protein production in microgravity opens up a whole new level of possibilities. Invitris

Rafał Mostowy discusses bacterial molecular warfare and possible ways to use phages, including engineered phages and virus-derived enzybiotics, against bacteria. TOK FM — OFF Czarek

Bacteriophage.news announces an affiliate partnership with Parallel Health. The post describes the company’s MD-03 Protocol as combining microbiome sequencing, personalized phage serums and ongoing clinical support. Bacteriophage.news

Second-year PhD student Milena Milovanović explains her thesis on how phages match their own DNA to their own proteins even when assembled outside a cell, using the PHEIGES test-tube system developed with the lab of Vincent Noireaux; she is

The Phage Collection Project was a flagship exhibit at the Royal Society Summer Science Exhibition from July 1–6, 2025. The team met more than 11,000 visitors and launched a phage-therapy VR experience. www.phage-collection.org

PhageLine is a podcast that unpacks the science of bacteriophages one paper at a time, with each episode discussing a recently published study. The podcast is generated using artificial intelligence, and infectious disease scientists review

ASM Health’s work at ASM Microbe included phage therapy, diagnostics, and microbiome medicines. A panel featured Steffanie Strathdee, Vivek Mutalik and Daria Van Tyne, and ASM launched its Phage Therapy Coordination Network. Neha Prasad

The article outlines a proposed Global Phage Fund that would link revenue from phage products with long-term support for discovery, development, manufacturing standards, regulatory alignment and equitable global access. Sebastian Leptihn

The official abstract book for the 9th World Conference on Targeting Phage Therapy includes over 48 contributions from 24 countries. Topics include phage therapy, One Health, and production, regulation and market access. Targeting Phage The

UCLA Samueli School of Engineering listed chemical engineering PhD graduate Yanxi (Steven) Yang among its 2025 schoolwide awardees, as a Harry M. Showman Prize (graduate) recipient. Yang hosts the "Phage Therapy Today" podcast (20 episodes,

The Best Arabic Phage Award 2025 honors Arab researchers who isolated phages in the MENA region, across medicine, agriculture, food safety and environmental applications. Phage Arab

Vésale Bioscience has become Inteliphage after five years, saying it is no longer just a research-driven biotech but is focused on bringing next-generation bacteriophage therapies into routine clinical care. The company says it is partnerin

Rhea Coler's lab at Seattle Children's develops bacteriophage therapies for tuberculosis, nontuberculous mycobacterial infections and cystic fibrosis lung disease, working with Graham Hatfull's lab at the University of Pittsburgh with Gates